United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $489.91, for a total value of $4,654,145.00. Following the transaction, the chief executive officer owned 130 shares of the company’s stock, valued at approximately $63,688.30. The trade was a 98.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Trading Down 1.2%

Shares of UTHR traded down $5.97 during trading hours on Friday, reaching $479.09. 33,379 shares of the company’s stock traded hands, compared to its average volume of 372,531. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $537.19. The stock has a market cap of $21.00 billion, a PE ratio of 17.17, a price-to-earnings-growth ratio of 1.77 and a beta of 0.84. The firm’s 50 day simple moving average is $483.09 and its 200-day simple moving average is $451.14.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same period last year, the firm posted $6.19 earnings per share. United Therapeutics’s quarterly revenue was up 7.4% on a year-over-year basis. As a group, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: UBS raised its price target on UTHR from $655 to $705 and maintained a Buy rating, implying roughly 45% upside vs. the current quote — a notable analyst endorsement that could attract buyers. Benzinga
• Negative Sentiment: Multiple insiders sold sizable blocks this week, creating downward pressure risk: CEO Martine A. Rothblatt sold 9,500 shares (~$4.65M) on Mar 4 (SEC filing). Directors and execs including Ray Kurzweil (4,910 sh), Tommy G. Thompson (2,000 sh) and EVP Paul A. Mahon (8,300 sh) also sold at ~$$483–$490 per share (SEC filings). The activity was flagged in a TipRanks piece summarizing the insider cash-outs. These disposals are large enough to influence sentiment even though many insiders retain significant holdings. TipRanks Rothblatt SEC Mahon SEC Kurzweil SEC Thompson SEC Causey SEC

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. AXQ Capital LP boosted its holdings in shares of United Therapeutics by 495.4% during the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock worth $1,117,000 after purchasing an additional 3,235 shares during the period. AE Wealth Management LLC increased its holdings in United Therapeutics by 396.3% during the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after purchasing an additional 3,424 shares during the period. Great Lakes Advisors LLC raised its position in United Therapeutics by 194.7% during the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after purchasing an additional 2,975 shares during the last quarter. Optimize Financial Inc purchased a new stake in United Therapeutics in the 3rd quarter worth approximately $444,000. Finally, Simplify Asset Management Inc. bought a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $8,351,000. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on UTHR. Bank of America reissued a “neutral” rating on shares of United Therapeutics in a research note on Wednesday, February 25th. UBS Group increased their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday. TD Cowen raised their price objective on United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Royal Bank Of Canada upped their target price on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Finally, HC Wainwright increased their price target on shares of United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $539.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.